MONTE ROSA THERAPEUTICS INC (GLUE)
US61225M1027 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A -40.56% | N/A 104.59% | N/A 324.55% | N/A 104.92% | N/A 70.74% | N/A 10.04% | N/A -13.61% | ||||||
| EBITDA YoY % growth | -7.92M | -27.47M -246.84% | -70.75M -157.55% | -108.63M -53.54% | -137.089M -26.20% | N/A 12.20% | N/A 6.78% | N/A -0.91% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -7.99M | -28.01M -250.56% | -72.88M -160.19% | -112.38M -54.20% | -143.311M -27.52% | N/A 13.77% | N/A -12.73% | N/A -16.60% | N/A 51.32% | N/A 128.07% | N/A 714.10% | N/A -2.86% | N/A 9.36% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2.29 20.50% | -2.64 -15.28% | N/A 41.55% | N/A 0.99% | N/A -8.82% | N/A 66.41% | N/A 241.55% | N/A 228.39% | N/A -22.33% | N/A -7.93% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.02 95.96% | -0.36 31.87% | -0.37 15.08% | -0.37 -25.92% | -0.33 -1,300.00% |
| Revenue Q2Q % growth | 8.645M | 2.55M 139.66% | 2.55M -45.69% | 2.55M -72.33% | 2.55M -70.50% |
| EBITDA Q2Q % growth | -24.48M 14.53% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -3.989M 88.56% | -37.23M -6.53% | -41.055M -25.77% | -42.585M -60.53% | -45.9M -1,050.60% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.29 58.57% | -0.50 | 0.21 | 41.55% |
| Q2 2024 Q2Q % growth | -0.43 39.44% | -0.55 | 0.12 | 21.93% |
| Q1 2024 Q2Q % growth | -0.53 18.46% | -0.58 | 0.05 | 9.30% |
| Q4 2023 Q2Q % growth | -0.58 7.94% | -0.34 | -0.24 | -69.89% |
| Q3 2023 Q2Q % growth | -0.70 -20.69% | -0.74 | 0.04 | 5.18% |
| Q2 2023 Q2Q % growth | -0.71 -24.56% | -0.71 | 0.00 | 0.56% |
| Q1 2023 Q2Q % growth | -0.65 -27.45% | -0.69 | 0.04 | 6.17% |
| Q4 2022 Q2Q % growth | -0.63 32.26% | -0.64 | 0.01 | 0.95% |
| Q3 2022 Q2Q % growth | -0.58 -34.88% | -0.61 | 0.03 | 5.21% |
| Q2 2022 Q2Q % growth | -0.57 84.30% | -0.55 | -0.02 | -3.39% |
| Q1 2022 Q2Q % growth | -0.51 | -0.53 | 0.02 | 4.21% |
| Q4 2021 Q2Q % growth | -0.93 | -0.51 | -0.42 | -82.96% |
| Q3 2021 Q2Q % growth | -0.43 | -0.45 | 0.02 | 4.62% |
| Q2 2021 Q2Q % growth | -3.63 | -0.41 | -3.22 | -784.18% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 9.216M | 2.673M | 6.543M | 244.78% |
| Q2 2024 Q2Q % growth | 4.695M | 1.376M | 3.319M | 241.21% |
| Q1 2024 Q2Q % growth | 1.064M | 1.428M | -364K | -25.49% |
| Q4 2023 Q2Q % growth | 15.453M | -15.453M | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 95.63% | 14.75% | 20.47% |
| Revenue | 0% | 376.83% | 68.12% | 137.55% |